

1           **Metabolomics Identifies and Validates Serum Androstenedione as Novel Biomarker for**  
2           **Diagnosing Primary Angle Closure Glaucoma and Predicting the Visual Field Progression**

3  
4 Shengjie Li<sup>1,2,3,4,5##\*</sup>, Jun Ren<sup>1#</sup>, Yichao Qiu<sup>1</sup>, Zhendong Jiang<sup>1</sup>, Mingxi Shao<sup>1</sup>, Yingzhu Li<sup>1</sup>, Jianing  
5 Wu<sup>1</sup>, Yunxiao Song<sup>6</sup>, Xinghuai Sun<sup>2,3,4,5</sup>, Shunxiang Gao<sup>2,3,4,5\*</sup>, Wenjun Cao<sup>1,2,3,4,5\*</sup>

6 1. Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan  
7 University, Shanghai, China

8 2. Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College,  
9 Fudan University, Shanghai, China

10 3. State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Fudan University,  
11 Shanghai, China

12 4. Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China

13 5. NHC Key Laboratory of Myopia, Fudan University, Shanghai, China

14 6. Department of Clinical Laboratory, Shanghai Xuhui Central Hospital, Fudan University, Shanghai,  
15 China

16 \* These authors contributed equally.

17 **Corresponding author:**

18 Shengjie Li, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Fenyang Road 83th,  
19 Shanghai 200031, China. E-mail: [lishengjie6363020@163.com](mailto:lishengjie6363020@163.com)

20 Shunxiang Gao, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Fenyang Road  
21 83th, Shanghai 200031, China. E-mail: [shunxianggao@163.com](mailto:shunxianggao@163.com)

22 Wenjun Cao, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Fenyang Road  
23 83th, Shanghai 200031, China. E-mail: [wgkjk@aliyun.com](mailto:wgkjk@aliyun.com)

24  
25 **Running head:** Androstenedione as a diagnostic and predictive biomarker for PACG

26 **Figures:** 7

27 **Tables:** 2

28 **Supplementary Tables:** 10

29 **Supplementary Figures:** 14



31 **Abstract**

32 **Background:** Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness  
33 in Asia, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines.  
34 A growing body of evidence shows metabolic alterations in patients with glaucoma. we aimed to  
35 develop and validate potential metabolite biomarkers to diagnose and predict the visual field  
36 progression of PACG.

37 **Methods:** Here, we used a 5-phases (discovery phase, validation phase 1, validation phase 2,  
38 supplementary phase, and cohort phase) multicenter (EENT hospital, Shanghai Xuhui central  
39 hospital), cross-sectional, prospective cohort study design to perform widely-targeted metabolomics  
40 and chemiluminescence immunoassay to determine candidate biomarkers. Five machine learning  
41 (random forest, support vector machine, lasso, K-Nearest neighbor, and Gaussian NB) approaches  
42 were used to identify an optimal algorithm. The discrimination ability was evaluated using the area  
43 under the receiver operating characteristic curve (AUC). Calibration was assessed by Hosmer-  
44 Lemeshow tests and calibration plots.

45 **Results:** Studied serum samples were collected from 616 participants, and 1464 metabolites were  
46 identified. Machine learning algorithm determines that androstenedione exhibited excellent  
47 discrimination and acceptable calibration in discriminating PACG across the discovery phase  
48 (discovery set 1, areas under the receiver operating characteristic curve [AUC] =1.0 [95%CI, 1.00-  
49 1.00]; discovery set, AUC=0.85 [95%CI, 0.80-0.90]) and validation phases (internal validation,  
50 AUC=0.86 [95%CI, 0.81-0.91]; external validation, AUC=0.87 [95%CI, 0.80-0.95]).  
51 Androstenedione also exhibited a higher AUC (0.92-0.98) to discriminate the severity of PACG. In  
52 the supplemental phase, serum androstenedione levels were consistent with those in aqueous humor  
53 ( $r=0.82$ ,  $P=0.038$ ) and significantly ( $P=0.021$ ) decreased after treatment. Further, cohort phase  
54 demonstrates that higher baseline androstenedione levels (hazard ratio=2.71 [95% CI: 1.199-6.104],  
55  $P=0.017$ ) were associated with faster visual field progression.

56 **Conclusion:** Our study identifies serum androstenedione as a potential biomarker for diagnosing  
57 PACG and indicating visual field progression.

58 **Keywords:** primary angle closure glaucoma; metabolomics; androstenedione; diagnose; predict;  
59 visual field progression; biomarker

## 60 **1. Background**

61 Glaucoma is the most frequent cause of irreversible blindness worldwide<sup>1</sup>, and its prevalence is  
62 increasing globally, making it a public health concern<sup>2</sup>. The primary form of glaucoma worldwide is  
63 Primary Open-Angle Glaucoma (POAG). However, in East Asian populations, Primary Angle-  
64 Closure Glaucoma (PACG) is predominant, affecting 70% of glaucoma patients globally.<sup>3-5</sup>. Hence,  
65 early detection of PACG and accurate prediction of visual field (VF) changes can potentially  
66 preserve vision and mitigate the risk of PACG advancement. Measurement of intraocular pressure,  
67 perimetry, gonioscopy and optical coherence tomography is the main diagnostic testing to assess for  
68 glaucoma and to monitor for disease progression<sup>6</sup>. However, the present clinical techniques are  
69 inadequate for the early diagnosis and prognosis of VF progression as they depend on specialized  
70 eye examination equipment and the expertise of ophthalmologists. Furthermore, patients seldom seek  
71 the services of an ophthalmologist until the symptoms worsen or visual acuity significantly  
72 deteriorates. Importantly, the He et al.<sup>7</sup> study taught us that performing laser iridotomy on patients  
73 with 180 degrees of angle closure does not prevent PACG, thus gonioscopy may not a good tool to  
74 help distinguish PACG from controls. Therefore, the development of a straightforward and  
75 dependable biomarker or biomarker panel to facilitate early detection and prognostication of  
76 progressive visual field loss in primary angle-closure glaucoma is imperative, rather than relying  
77 solely on the expertise of ophthalmologists and specialized equipment.

78 Multiple etiology and risk factors lead to the onset/development of PACG in humans, which involves  
79 a tremendous flow of physiological changes, genetic factors, and metabolic adaptations<sup>8</sup>. Both  
80 physiological changes, genetic factors, and metabolic adaptations should lead to profound changes in  
81 most metabolic pathways. Small molecule metabolites, as crucial biomarkers of cellular function<sup>9</sup>,  
82 which identifies and quantified by metabolomics, are the omics product closest to clinical  
83 phenotypes<sup>10</sup>. A burgeoning corpus of evidence indicates metabolic changes in individuals afflicted  
84 with glaucoma<sup>11-15</sup>. Nevertheless, extant metabolomics research on glaucoma is constrained by  
85 inadequate sample sizes, a dearth of validation sets to corroborate findings, and an absence of  
86 specificity analyses. Notably, investigations have yet to comprehensively characterize the serum  
87 metabolome in sizable cohorts to identify putative biomarkers capable of distinguishing patients with  
88 PACG from healthy controls.

89 In this study, a cross-sectional and prospective cohort design was employed to systematically profile  
90 blood metabolites using widely-targeted metabolomics and chemiluminescence immunoassay in both  
91 patients with primary angle-closure glaucoma (PACG) and control individuals. The objectives of the  
92 study were to characterize the metabolic profile associated with PACG, identify potential blood  
93 diagnostic biomarkers of PACG, assess the specificity of diagnostic biomarkers for PACG of any  
94 severity, and verify the biomarkers used to predict the visual field progression of PACG.

95

## 96 **2. Methods**

### 97 **2.1 Participant**

98 From January 2020 to December 2021, newly diagnosed PACG and age-sex-matched controls were  
99 recruited from the Eye Center of Fudan University and Shanghai Xuhui Central hospital. Detailed  
100 ophthalmic examinations and medical examinations were described in the supplementary material.  
101 Approval from the Institutional Review Board/Ethics Committee (2020[2020013]) was obtained  
102 from the Ethics Committee of the Eye and ENT Hospital, and the study adhered to the principles of  
103 the Declaration of Helsinki. Informed consent was obtained from all subjects.

104 A glaucoma specialist diagnosed PACG. The diagnostic criteria for PACG were described  
105 previously<sup>16-18</sup> and detailed in the supplementary material. The inclusion and exclusion criteria of  
106 patients with PACG were described previously<sup>16-18</sup> and detailed in the supplementary material. The  
107 methods performed for VF analysis were done as previously described<sup>16,18</sup> and detailed in the  
108 supplementary material. Previously described methods<sup>16,18-20</sup> were performed for the determination  
109 of functional PACG VF loss progression according to an event-based analysis modified for Octopus  
110 perimetry.

### 111 **2.2 Study design**

112 A cross-sectional, multicenter, prospective cohort study design. In the cross-sectional study, a total of  
113 616 patients and controls were prospectively enrolled from the Eye Center of Fudan University and  
114 Shanghai Xuhui Central hospital which was divided into 4 phases (discovery phase [discovery set 1,  
115 the discovery set 2], validation phase 1 [external validation], validation phase 2 [internal validation],  
116 supplemental phase) from eight districts in China (Figure S1). The 5 phases of the study are  
117 independent and are shown in Figure 1. The discovery set 1 was composed of 80 serum samples

118 from PACG patients and 60 samples from controls which was enrolled from Eye Center of Fudan  
119 University between January 2020 to June 2020. The discovery set 2 was composed of 100 serum  
120 samples from PACG patients and 80 samples from controls which was enrolled from Eye Center of  
121 Fudan University between July 2020 to December 2020. The differential metabolites of discovery  
122 set 1 and discovery set 2 were obtained by widely-targeted metabolomics. The intersection of the  
123 differential metabolites of the two discovery sets was used as a candidate biomarker. For validation  
124 phase 1, serum samples from 70 PACG patients and 50 controls were collected which was enrolled  
125 from Shanghai Xuhui Central hospital between January 2020 to December 2020. Candidate  
126 biomarkers were validated in validation phase 1 using widely-targeted metabolomics, and potential  
127 biomarkers were obtained. For validation phase 2, serum samples from 98 PACG patients and 78  
128 controls were collected which was enrolled from Eye Center of Fudan University between January  
129 2021 to December 2021. Potential biomarkers were validated in validation phase 2 using  
130 chemiluminescence methods. For the supplemental phase, we used widely-targeted metabolomics to  
131 investigate whether the same potential biomarkers were present in PACG patients' aqueous humor.  
132 All the clinical characteristics (Age, sex, BMI, hypercholesterolemia, hypertension, diabetes,  
133 smoking, drinking) were matched between PACG and controls in the 4 phases.  
134 In the prospective cohort study, 98 newly diagnosed PACG patients were included from the Eye  
135 Center of Fudan University between January 2020 and December 2020. All participants visited once  
136 every six months to allow regular assessment of PACG disease progression (the minimum follow-up  
137 period was set to 24 months). Serum samples from 98 PACG patients were collected and measured  
138 using chemiluminescence methods. Detailed information of patients follow up were described as  
139 previously<sup>16,18</sup>.

## 140 **2.3 Sample preparation**

### 141 **2.3.1 Sample collection**

142 The blood was collected prior to the medical or surgical treatment. Briefly, subjects were asked to  
143 ensure about eight-ten hours of fasting before sampling. Venous blood samples were collected in  
144 heparinized tubes between 7:00-9:30 am. The clinical laboratory obtained the sample at about 10:00  
145 am and centrifuged them at 3000rpm for 10min. Then serum was collected into a sterilized cryotube  
146 and immediately stored at -80°C for metabolomic analysis.

147 The acquisition of aqueous humor was described previously<sup>13</sup>. Aqueous humor (AH) was collected  
148 by skilled ophthalmologists during the surgical treatment of PACG and cataract patients. AH was  
149 obtained at the start of the procedure using a fine-bore needle during a corneal paracentesis.  
150 Following that, AH samples were quickly transferred to sterile cryotubes and kept at -80 °C for  
151 metabolomic analysis.

### 152 **2.3.2 Sample preprocessing**

153 The same internal standard was added to each sample during metabolite extraction (L-2-  
154 chlorophenylalanine, 4-Fluoro-L- $\alpha$ -phenylglycine, [2H5]-Kynurenic Acid, [2H5]-Phenoxy acetic  
155 Acid, Indole-3-butyric-2,2-d<sub>2</sub> Acid, LysoPC 19:0, DL-3-Indole-lacticacid). Before extraction, the  
156 serum was thawed on ice, vortex for 10s and mixed well. 300 $\mu$ L of pure cold methanol was added to  
157 50 $\mu$ L of serum, swirled for 3min, and centrifuged at 12000 rpm for 10min at 4°C. After  
158 centrifugation, transfer the supernatant into a new centrifuge tube and place it in a -20°C refrigerator  
159 for 30 minutes. The sample was thawed on ice and centrifuged at 12000r/min for 3 minutes—  
160 Transfer 180 $\mu$ L of the supernatant to the injection vial for mass spectrometry analysis. Quality  
161 control (QC) samples are generated by pooling all the serum samples to monitor the retention time  
162 and signal intensity consistency. Equal volumes (10  $\mu$ L) of all serum samples were combined to  
163 generate quality control (QC) samples, which were employed to monitor the repeatability of the  
164 analysis. During the mass spectrometry analysis, one QC sample was included in every ten samples  
165 to ensure the consistency of the analytical process(sheet1). The PACG and control groups' serum  
166 samples were randomly arranged and analyzed. The laboratory conducting the metabolomics  
167 measurements was blinded to the samples' case/control/QC status.

## 168 **2.4 Analytical methods**<sup>21</sup>

### 169 **2.4.1 Untargeted metabolomics analysis**

170 Ultra Performance Liquid Chromatography (UPLC) (ExionLC AD, AB SCIEX) separation was  
171 performed using Waters ACQUITY HSS T3 (2.1 $\times$ 100mm, 1.8 $\mu$ m). The oven temperature was set to  
172 40°C, and the sample injection volume was 5  $\mu$ L. Metabolites were eluted from the column at a flow  
173 rate of 0.35 mL/min. Mobile phases for UPLC consisted of 0.1% acetic acid in water (phase A) and  
174 0.1% acetic acid in acetonitrile (phase B). The following gradient elution program was employed: 0-  
175 10min: linear gradient from 5% to 90% B; 10-11min: 90% B; 11-11.1min: linear gradient from 90%

176 to 5% B; 11.1-14min: 5% B. Metabolic extracts mixture (QC sample) were analyzed by the triple  
177 time of flight (TOF) mass spectrometer (TripleTOF 6600, AB SCIEX) in both positive and negative  
178 ionization modes. The scan range was 50-1,000 m/z. Electrospray ionization (ESI) source conditions  
179 were set as follows: ion spray voltage (IS) 5500V (positive), -4500V (negative); ion source gas I  
180 (GSI), gas II (GASII), curtain gas (CUR) was set at 50,50, and 25 psi, respectively; collision energy  
181 (CE) 30V.

#### 182 **2.4.2 Widely targeted detection conditions**

183 UPLC (ExionLC AD, AB SCIEX) separation was performed using Waters ACQUITY UPLC  
184 C18(2.1×100mm, 1.8µm). The oven temperature was set to 40°C, and the sample injection volume  
185 was 2 µL. Metabolites were eluted from the column at a flow rate of 0.35 mL/min. Mobile phases for  
186 UPLC consisted of 0.1% acetic acid in water (phase A) and 0.1% acetic acid in acetonitrile (phase B).  
187 The following gradient elution program was employed: 0-11min: linear gradient from 5% to 90% B;  
188 11-12min: 90% B; 12-12.1min: linear gradient from 90% to 5% B; 12.1-14min: 5% B. Metabolic  
189 extracts of each sample were analyzed by the triple quadrupole-linear ion trap mass spectrometer  
190 (QTRAP 6500, AB SCIEX) in both positive and negative ionization modes. ESI source conditions  
191 were set as follows: ion spray voltage (IS) 5500V (positive), -4500V (negative); ion source gas I  
192 (GSI), gas II (GASII), curtain gas (CUR) was set at 50,50, and 25 psi, respectively. Each ion pair is  
193 scanned for detection based on optimized voltage and CE.

#### 194 **2.4.3 Metabolite profiling**

195 Mixed samples (QC sample) were made and tested by AB Triple TOF 6600 mass spectrometer, the  
196 metabolites identified base on public database including Metware public database (Metlin, HMDB,  
197 KEGG), and MetDNA. The detected metabolites of QC sample (metabolites with a total score > 0.5)  
198 add Metware in-house database to be a new whole database. MRM was used for each samples to  
199 determine the final ion pair and other information. Based on the new database, Q-trap 6500 was used  
200 to quantify all samples accurately. The workflow of mass spectrometry is detailed in Figure S2.

#### 201 **2.4.4 Data processing**

202 All LC-MS data were processed using Analyst 1.6.3 for imputing raw, peak picking, alignment,  
203 normalization, and to produce peak intensities for retention time and m/z data pages. The features were  
204 selected based on their CV with QC samples. Features with CVs of more than 15% were eliminated.



#### 205 **2.4.5 Chemiluminescence immunoassay**

206 Serum levels of androstenedione were measured using a commercially available kit (Snibe  
207 Diagnostics, Shenzhen, China) and were determined using the chemiluminescent immunoassay  
208 method by Roche Cobase e 601 (Germany).

#### 209 **2.5 Sample size and missing value**

210 In the cross-sectional study, to calculate the minimum total sample size, we used an open-source  
211 calculator based on the methods described by Obuchowski et al.<sup>22</sup> and Li et al.<sup>23</sup>. The input  
212 parameters were specificity = 0.9 (allowable error = 0.05), sensitivity = 0.9 (allowable error = 0.05),  
213  $\alpha = 0.05$  (2-tailed). Based on this calculation, the minimum sample size required for the new  
214 biomarker was 98 per phase.

215 An unreliable conclusion would result from missing data, which would introduce bias. Thus no  
216 patients with missing data were included in this study. In this study, a total of 48 participants (lack of  
217 VF value = 18, lack of medication history record = 12, lack of intraocular pressure [IOP] value = 10,  
218 loss to follow-up = 8) were excluded due to with missing data.

#### 219 **2.6 Statistical analysis**

220 Normality was assessed using the Shapiro–Wilk W-test. Independent student’s t-test, Kruskal-Wallis  
221 test, one-way ANOVA, Wilcox test, and chi-square tests were used when appropriate. Results are  
222 presented as frequency and percentage for categorical variables, mean  $\pm$  SD for normally distributed  
223 continuous variables, and median (interquartile range) for not normally distributed continuous  
224 variables. The Spearman correlation test was used to determine the significance of the correlations  
225 between the variables.

226 Diagnostic efficiency was evaluated using receiver operating characteristic (ROC) curves. Five  
227 machine learning (random forest, support vector machine, lasso, K-nearest neighbor [KNN], and  
228 Gaussian Naive Bayes [NB]) approaches were used to identify an optimal algorithm. The Youden  
229 index maximizing sensitivity plus specificity is applied to determine the best cutoff value, sensitivity,  
230 specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were also  
231 calculated. Hosmer-Lemeshow tests were used to assess the goodness of fit. The calibration of the  
232 biomarker was assessed by computing the calibration plot. Hanley-McNeil method was used to  
233 compare these AUCs.

234 Unsupervised principal component analysis (PCA) was performed by statistics function prcomp  
235 with R. The data was unit variance scaled before unsupervised PCA. Supervised orthogonal  
236 projections to latent structures-discriminate analysis (OPLS-DA) were applied to obtain a higher  
237 level of group separation and a better understanding of variables responsible for classification.  
238 Heatmaps of samples and metabolites were carried out by R package (ComplexHeatmap; heatmap).  
239 In order to evaluate the binding mode of metabolites and proteins, Autodock Vina v.1.2.2 was used to  
240 analyze molecular docking. Fold change= the characteristic peak area of metabolites in the PACG  
241 group / the control group.

242 Identified metabolites were annotated using the KEGG Compound database  
243 (<http://www.kegg.jp/kegg/compound/>). Then annotated metabolites were mapped to the KEGG  
244 Pathway database (<http://www.kegg.jp/kegg/pathway.html>). Significantly enriched pathways were  
245 identified with a hypergeometric test's p-value for metabolites.

246 Cox proportional hazards analysis was also carried out to investigate the relationship between  
247 baseline androstenedione levels and VF progression loss. The HRs and baseline characteristics that  
248 would assist in categorizing participants into the non-progressing PACG group over the follow-up  
249 period were determined using Cox proportional hazards models. Kaplan-Meier plots were used to  
250 study the survival results, and the log-rank test was applied to see whether there were any differences  
251 between the produced plots.

252 All statistical analyses were performed using R programming language and SPSS 13.0 (SPSS Inc.,  
253 Chicago, IL, USA), a list of statistical approaches and packages detailed in table S1. P-values less  
254 than 5% were considered statistically significant.

### 255 **Role of funding sources**

256 The funder of the study had no role in study design, data collection, data analysis, data interpretation,  
257 or writing of the report.

258

## 259 **3. Results**

### 260 **3.1 Metabolomic analyses in samples from PACG patients and normal controls**

261 The design of this study is depicted in Figure 1, while the clinical features of all participants in the  
262 four phases of the study are presented in Tables 1 (Phases 1-3) and S2-S3 (Phase 4). All clinical

263 characteristics, including age, sex, BMI, hypercholesterolemia, hypertension, diabetes, smoking, and  
264 drinking, were carefully matched between the PACG and normal control groups across all four  
265 phases.

266 Following rigorous quality control, data filtering, and normalization procedures, a total of 1464  
267 metabolites were identified across the various samples (N = 440). During the discovery phase, the  
268 OPLS-DA analysis revealed notable distinctions between participants with primary angle-closure  
269 glaucoma (PACG) and those without the condition (Figure 2A). Volcano plots (Figure 2B) were  
270 generated using metabolites exhibiting a false discovery rate [FDR] of less than 0.1 and fold changes  
271 greater than 1.15 or less than 0.85. In discovery sets 1 and 2, 268 metabolites (21.5%) and 117  
272 metabolites (9.6%), respectively, were found to be significantly altered between PACG and normal  
273 subjects.

274 The Venn diagram depicted in Figure 2C illustrates the presence of 32 metabolites that were found to  
275 be common in both discovery set 1 (as presented in table S4) and discovery set 2 (as presented in  
276 table S5). The parameters used for detecting these 32 differential metabolites are detailed in Table S6.  
277 Subsequently, these differential metabolites were utilized for conducting clustering analysis, which is  
278 visually represented in the form of a heatmap for both discovery set 1 (Figure 2D) and discovery set  
279 2 (Figure 2E). These 32 differential metabolites were mainly related to alcohol and amines, amino  
280 acid and its metabolomics, benzene and substituted derivatives, fatty acid, heterocyclic compounds,  
281 hormones, and hormone-related compounds, nucleotide and its metabolomics, organic acid and its  
282 derivatives class (Figure 2D, 2E).

### 283 **3.2 The blood differential metabolite discriminates PACG from normal**

284 Can these metabolites in blood differentials be considered as potential biomarkers for PACG? In  
285 order to investigate this, we computed the area under the curve (AUC) for each of the 32 differential  
286 metabolites to evaluate their discriminatory capacity in distinguishing PACG from healthy  
287 individuals using five machine learning techniques (random forest, support vector machine, lasso,  
288 KNN, and Gaussian NB). Among these approaches, KNN demonstrated the highest performance in  
289 identifying PACG from normal controls. Subsequently, a 2-column heatmap was generated to display  
290 the resulting area under the curve (AUC) values for discovery set 1 and discovery set 2, respectively,  
291 as depicted in Figure 3A. The receiver operating characteristic (ROC) analysis of 32 metabolites

292 revealed AUC values ranging from 0.74 to 1.0 in discovery set 1 and 0.72 to 1.0 in discovery set 2  
293 for distinguishing PACG from normal subjects. The eigenmetabolite of the 32-metabolite cluster  
294 between PACG and normal subjects is illustrated in Figure 4B and 4C. The discriminatory accuracy  
295 of the metabolite in differentiating PACG from normal subjects using random forest, support vector  
296 machine, lasso, and Gaussian NB is presented in Figure S3.

297 The present study reveals that the eigenmetabolite levels were markedly elevated ( $P < 0.001$ ) in the  
298 normal group compared to the PACG group, as evidenced by the results obtained from discovery set  
299 1 (Figure 3B) and discovery set 2 (Figure 3C). These findings provide compelling evidence that the  
300 heightened risk of PACG is linked to a robust blood metabolite signature.

### 301 **3.3 Biomarker discovery to discriminates PACG from normal**

302 Figure 3A illustrates that 32 metabolites were verified during the discovery phase and were  
303 subsequently identified as potential biomarkers. Figure 4A depicts a correlation analysis between  
304 ocular clinical characteristics and the 32 potential biomarkers discovered during the PACG discovery  
305 phase. Notably, a significant positive correlation was observed between androstenedione and the  
306 mean deviation of the VF (MD) ( $r = 0.45$ ,  $P < 0.001$ ). This correlation was also observed in discovery  
307 set 1 (Figure S3,  $r = 0.37$ ,  $P < 0.001$ ) and discovery set 2 (Figure S4,  $r = 0.50$ ,  $P < 0.001$ ), respectively. A  
308 statistically insignificant ( $P > 0.05$ ) correlation was observed between ocular clinical characteristics  
309 and the remaining 31 potential biomarkers, as depicted in Figure 3A, Figure S3, and Figure S4.  
310 Notably, the level of androstenedione was found to be significantly higher in PACG patients than in  
311 normal subjects in both discovery set 1 (Figure 4B,  $P = 0.0081$ , Normal:  $33987 \pm 11113$ , PACG:  $42852$   
312  $\pm 20767$ ) and discovery set 2 (Figure 4C,  $P = 0.0078$ , Normal:  $31559 \pm 10975$ , PACG:  $37934 \pm 18529$ ).  
313 Additionally, high levels of androstenedione were identified as an independent risk factor for PACG,  
314 as shown in Table S7. Figure S5 (Discovery set 1) and Figure S6 (Discovery set 2) illustrate the  
315 levels of the remaining 31 metabolites between PACG patients and normal subjects. Based on the  
316 preceding analysis, androstenedione was chosen using KNN due to its ability to differentiate between  
317 PACG and normal subjects. In discovery set 1, the AUC for PACG versus control was 1.0 (95% CI,  
318 1.0 to 1.0), as shown in Figure 4D and Table S8. Similarly, in discovery set 2, PACG was identified  
319 with an AUC of 0.85 (95% CI, 0.80 to 0.90) when compared to control individuals, as depicted in  
320 Figure 4E and Table S8.

### 321 **3.4 Biomarker validation in two independent validation phases**

322 During the validation phases, Androstenedione was evaluated as a biomarker signature. The samples  
323 from validation phase 1 were subjected to LC-MS analysis for widely-targeted metabolomics, which  
324 revealed significant differences between PACG and normal participants, as demonstrated by the  
325 OPLS-DA analysis (Figure S7). In validation phase 2, a chemiluminescence immunoassay method  
326 was developed to enable precise quantification of serum androstenedione levels in a convenient and  
327 rapid manner.

328 During validation phase 1 and 2, the level of androstenedione was found to be significantly higher in  
329 individuals with PACG compared to normal subjects (Figure 5A,  $P=0.0042$ , Normal:  $60737 \pm 28078$ ,  
330 PACG:  $82394 \pm 33994$ ; Figure 5B,  $P=0.0034$ , Normal:  $1.552 \pm 0.489$ , PACG:  $1.825 \pm 0.6876$ ). The  
331 performance of androstenedione was evaluated using the AUC in ROC analysis. The AUC for PACG  
332 versus control was 0.87 (95% CI, 0.80 to 0.95) in validation phase 1, as depicted in Figure 5C and  
333 Table S8. In validation phase 2, a consistent performance of androstenedione (AUC, 0.86, 95% CI,  
334 0.81 to 0.91) was observed (Figure 5D, Table S8).

### 335 **3.5 Biomarker validation in male and female subgroups**

336 Validation of androstenedione as a biomarker for PACG necessitates consideration of sex, as males  
337 exhibit 5-10 times higher levels of this hormone than females. Accordingly, the subjects were  
338 stratified into male and female subgroups.

339 Figure S8 demonstrates that in the discovery phase, the AUC for PACG compared to control was 1.0  
340 (95% CI, 1.0 to 1.0) in the male subgroup (Figure S8A), and 0.91 (95% CI, 0.85 to 0.98) in the  
341 female subgroup (Figure S8B). In validation phase 1, the AUC for PACG versus control was 0.83 (95%  
342 CI, 0.73 to 0.92) in the male subgroup (Figure S8C), and 1.0 (95% CI, 1.0 to 1.0) in the female  
343 subgroup (Figure S8D). In validation phase 2, the AUC for PACG versus control was 1.0 (95% CI,  
344 1.0 to 1.0) in the male subgroup (Figure S8E), and 0.88 (95% CI, 0.79 to 0.98) in the female  
345 subgroup (Figure S8F).

### 346 **3.6 Androstenedione associates with severity of PACG**

347 The present study aimed to examine the potential association between serum androstenedione levels  
348 and the clinical severity of PACG. PACG severity was categorized into mild ( $MD \leq 6$ ), moderate (6-  
349 12), and severe ( $MD > 12$ ) based on the MD value. The results from both discovery set 1 (Figure S9A,

350 Mild:32600 ± 17011, Moderate:33215 ± 17855, Severe:46060 ± 21789) and discovery set 2 (Figure  
351 S9B, Mild:27866 ± 19873, Moderate:27057 ± 13166, Severe:43972 ± 19234) indicated that the mean  
352 serum androstenedione levels were significantly higher in the severe PACG group compared to the  
353 moderate and mild PACG groups (P<0.001). These findings were further validated in both validation  
354 phase 1 (Figure S9C, Mild:75726 ± 45719, Moderate:65798 ± 30610, Severe:94348 ± 30858) and  
355 validation phase 2 (Figure S9D, Mild:1.121 ± 0.3143 ng/ml, Moderate:1.461 ± 0.4391 ng/ml,  
356 Severe:2.147 ± 0.6476 ng/ml).

357 A correlation analysis was conducted to examine the relationship between MD and androstenedione.  
358 Notably, a statistically significant positive correlation was found between MD and androstenedione  
359 in both discovery set 1 (Figure S3, r=0.37, P<0.001) and discovery set 2 (Figure S4, r=0.50,  
360 P<0.001). This finding was further confirmed in validation phase 2 (Figure S9E, r=0.61, P<0.001).  
361 Subsequently, the diagnostic potential of androstenedione in distinguishing the severity of PACG was  
362 investigated. An AUC was calculated for each severity of PACG to evaluate the discriminatory  
363 accuracy of androstenedione in distinguishing between mild, moderate, and severe cases. The results  
364 of ROC analysis indicated AUC values ranging from 0.75 to 0.95 in discovery set 1 (Figure S10A,  
365 Table S8) and 0.94 to 0.99 in discovery set 2 (Figure S10B, Table S8) when using KNN machine  
366 learning algorithms. The validity of androstenedione in distinguishing the severity of PACG was  
367 demonstrated through consistent performance in both validation phase 1 (Figure S10C, Table S8,  
368 AUC of 0.64-0.97) and validation phase 2 (Figure S10D, Table S8, AUC of 0.98-1.0). Additionally,  
369 when mild and moderate cases were combined, the AUC for mild and moderate versus severe was  
370 0.94 (95% CI 0.89 to 0.99) in discovery set 1 (Figure S9F, Table S8), 0.93 (95% CI 0.88 to 0.98) in  
371 discovery set 2 (Figure S9G, Table S8), 0.92 (95% CI 0.85 to 0.99) in validation phase 1 (Figure S9H,  
372 Table S8), and 0.98 (95% CI 0.96 to 1.0) in validation phase 2 (Figure S9I, Table S8).

### 373 **3.7 Clinical value of androstenedione in patients with PACG**

374 The lack of specificity of serum biomarkers remains a significant obstacle to the clinical application  
375 of such markers. To investigate temporal changes in androstenedione levels during the initial  
376 diagnosis and post-treatment period, we conducted a random analysis of nine pairs of blood samples  
377 from patients taken before and three months after surgical treatment (Figure 6A). Our findings  
378 indicate a significant decrease in androstenedione levels in the post-treatment serum of the nine

379 patients compared to the pre-treatment serum ( $P = 0.021$ , Figure 6B).

380 A case-control study (PACG=7, Cataract=11) (Figure 6C) was conducted to investigate the potential  
381 elevation of aqueous humor levels of androstenedione in patients. The findings revealed a  
382 statistically significant increase ( $P=0.011$ ) in the levels of androstenedione in the aqueous humor of  
383 patients with PACG compared to those with cataracts (Figure 6D). Additionally, a significantly  
384 positive correlation between MD and aqueous humor levels of androstenedione was observed (Figure  
385 6E,  $r=0.98$ ,  $P<0.001$ ). The mean aqueous humor levels of androstenedione were found to be  
386 significantly higher ( $P<0.001$ ) in the severe PACG group compared to the moderate and mild PACG  
387 groups (Figure 6F). Subsequently, an examination was conducted on seven paired serum-aqueous  
388 humor samples obtained from identical PACG patients to ascertain the presence of a consistent  
389 pattern within the same individuals. A statistically significant correlation was observed between the  
390 levels of androstenedione in serum and aqueous humor ( $r=0.82$ ,  $P=0.038$ ) (Figure 6G).

### 391 **3.8 Calibration ability of androstenedione on discovery phase and validation phase**

392 Figure S11 displays the calibration plots for both the discovery and validation phases, which  
393 effectively validate the calibration performance of serum androstenedione for probability. The plots  
394 demonstrate a high level of agreement between predicted and observed values in both discovery set 1  
395 (Figure S11A) and discovery set 2 (Figure S11B). The Hosmer-Lemeshow test yielded a  
396 nonsignificant statistic in the discovery set 1 ( $\chi^2=0$ ,  $P=1$ ) and discovery set 2 ( $\chi^2=6.16$ ,  $P=0.10$ ),  
397 indicating no departure from a perfect fit. Validation phase 1 (Figure S11C,  $\chi^2=5.14$ ,  $P=0.14$ ) and  
398 validation phase 2 (Figure S11D,  $\chi^2=1.25$ ,  $P=0.26$ ) resulted in similar performance.

### 399 **3.9 Androstenedione could predict VF progression in patients with PACG**

400 This study comprised 97 participants diagnosed with PACG, selected based on the screening criteria  
401 and followed up for a period of 24 months. In cases of bilateral PACG, one eye was selected at  
402 random. Of the total participants, 44 (45.36%) exhibited glaucoma progression, as evidenced by  
403 visual field (VF) loss. The demographic and ocular features of the VF progressing and non-  
404 progressing groups at baseline are presented in Table S9.

405 The patients in the progression group exhibited a statistically significant increase ( $P<0.001$ ) in the  
406 mean serum levels of androstenedione compared to those in the non-progressing group (refer to  
407 Table S9). Furthermore, the multivariate Cox analysis revealed that the baseline levels of



408 androstenedione (HR=2.71, 95% CI=1.20–6.10, P=0.017) were significantly associated with  
409 glaucoma progression, as determined by the VF loss results (Table 2). Figure 7 displays the Kaplan-  
410 Meier survival curves. The results of the survival analysis revealed a statistically significant increase  
411 in the proportion of patients with elevated androstenedione levels who experienced VF progression  
412 in PACG (log-rank test, P<0.001, Figure 7A). Comparable findings were observed in both the female  
413 (log-rank test, P=0.0042, Figure 7B) and male (log-rank test, P=0.0014, Figure 7C) subgroups.

414

#### 415 **4. Discussion**

416 The delayed identification of PACG is a notable contributor to patients' impaired vision and  
417 irreversible blindness. Regrettably, existing medical protocols do not advocate for the use of blood-  
418 based biomarkers to diagnose and prognosticate PACG. Consequently, it is imperative to develop  
419 novel, uncomplicated, and practicable approaches to improve the early detection of PACG and its  
420 predictive accuracy. To address the significant challenge at hand, the present study conducted a  
421 cross-sectional and prospective cohort investigation utilizing high-throughput, widely-targeted  
422 metabolomics and targeted chemiluminescence immunoassay on blood samples obtained from a  
423 substantial number of patients diagnosed with PACG and healthy individuals. The findings of this  
424 study reveal, for the first time, that androstenedione exhibits a reasonable level of precision (AUC,  
425 0.85-1.0) in distinguishing between PACG and control groups in blood samples. Additionally, the  
426 baseline levels of androstenedione may serve as a valuable predictor of glaucomatous visual field  
427 progression.

428 Some metabolites have been proposed to have a potential role in discriminating PACG from normal,  
429 but validation studies in larger cohorts still need to be completed. Rong et al.<sup>14</sup> conducted a case-  
430 control (PACG=38, normal=48) study using gas chromatography-mass spectrometry and reported  
431 that palmitoleic acid, linoleic acid,  $\gamma$ -linolenic acid, and arachidonic acid were identified as essential  
432 metabolites associated with PACG, but diagnostic accuracy is unknown. In our study, these  
433 metabolites were also detected, but diagnosis accuracy (AUC<0.7) was limited. Qin et al.<sup>24</sup> measured  
434 plasma twenty-two free fatty acids (FFA) and six lipid classes using metabolomics analysis, shown  
435 that docosahexaenoic acid (DHA) and total saturated fatty acids may be screening indices (AUC,  
436 0.82-0.85) for PACG patients but lack validation set to confirm the results. DHA (AUC, 0.74-0.85),



437 FFA (22:6) (AUC, 0.74-0.85), and FFA (18:4) (AUC, 0.79-1.0) was also shown a diagnose value for  
438 PACG patients in the discovery set of our study (Figure 3A), but the robustness and diagnose  
439 accuracy was weaker than androstenedione (AUC, 0.85-1.0) (Table S10). The contribution of  
440 previous metabolites to PACG diagnosis was small, which prompted us to conduct a trial designed to  
441 develop biomarkers.

442 In this study, androstenedione levels achieved better diagnostic efficiency and robust calibration  
443 across the discovery and validation sets. The transformation of normal subjects into PACG is a  
444 chronic stepwise process. Given this, screening healthy individuals and those with a family history of  
445 the disease is vital. Another important finding of this research was that the level of serum  
446 androstenedione retained its diagnostic efficiency for distinguishing the severity of PACG.  
447 Furthermore, serum androstenedione levels incrementally increased from mild to moderate to severe  
448 PACG, suggesting that serum androstenedione levels may accurately reflect the progression/severity  
449 of PACG. Furthermore, androstenedione levels at baseline were a new biomarker for predicting  
450 glaucomatous VF progression. Hence, serum androstenedione levels may provide a new biomarker  
451 for early detection and monitoring/predicting PACG severity/progression.

452 In the supplemental phase, we asked whether the serum levels of androstenedione were significantly  
453 correlated with aqueous humor levels of androstenedione from the same PACG patients, which is an  
454 important criterion for application as a routine clinical biomarker and to explore the biological  
455 function in PACG. Fortunately, the levels of aqueous humor androstenedione were positively  
456 correlated ( $r=0.82$ ,  $P=0.038$ ) with serum levels. Meanwhile, the levels of aqueous humor  
457 androstenedione incrementally increased from mild-moderate to severe PACG. Furthermore, the  
458 levels of aqueous humor androstenedione remained higher in PACG than in cataracts. Together, these  
459 results confirm that androstenedione can serve as a novel biomarker for early detection and  
460 monitoring of the progression/severity of PACG.

461 In clinical practice, oral topical glaucoma medications and laser peripheral iridectomy were the  
462 primary therapies used to treat PACG. However, the effects of these therapies are mainly estimated  
463 by measurement of intraocular pressure and optical coherence tomography. Thus, we have wondered  
464 whether, by dynamic detection, serum androstenedione levels could reflect the therapeutic effect of  
465 these therapies. In the supplemental phase (fourth phase), in a small cohort of 9 PACG patients

466 treated with laser peripheral iridectomy or oral topical glaucoma medications, which showed a better  
467 prognosis, 7 of 9 exhibited decreased levels of serum androstenedione. These results shed new light  
468 on the monitor the effect of therapy; however, these should be verified in a larger cohort.

469 The main strength of our study is its robustness. We conducted a 5-phase study (discovery set  
470 [discovery set 1, the discovery set 2], validation phase 1, validation phase 2, supplemental phase, and  
471 cohort phase). We used large and well-characterized patients with adequate controls to confirm the  
472 results. Widely-targeted metabolomics and target chemiluminescence immunoassay methods provide  
473 high reliability of the metabolite. Androstenedione achieved better diagnostic accuracy across the  
474 discovery and validation sets, with AUC varying between 0.85 and 1.0. Interestingly, baseline  
475 androstenedione levels can predict glaucoma progression via VF loss results. Of note, the clinical  
476 practice of androstenedione in patients with PACG was analyzed by supplemental phase.

477 The metabolites identified by this study match PACG pathophysiological concepts. Pathway  
478 enrichment analysis demonstrated that these 32 significantly altered metabolites primarily belonged  
479 to 16 pathways (Figure S12). Among the top altered pathways, steroid hormone biosynthesis appears  
480 to be the critical node to high-match PACG pathophysiological concepts<sup>25,26</sup>: it connects with  
481 androstenedione. The molecular formula of androstenedione is shown in Figure S13. Steroid  
482 hormone biosynthesis appears to be a key node in the pathophysiological concept of highly matched  
483 PACG, but high enrichment is observed in metabolic pathways. Hormones play critical roles in  
484 various physiological functions, such as metabolism, immune responses, and inflammation  
485 regulation. In a related study on fatigue experienced during Androgen Deprivation Therapy (ADT),  
486 marked disparities were found in metabolite levels in the steroid hormone biosynthesis pathways,  
487 underscoring their significance in metabolic shifts. These insights highlight the intricate  
488 interconnection between steroid hormone biosynthesis and other metabolic pathways<sup>27,28</sup>. The sex  
489 hormones pathway is a vital component of steroid hormone biosynthesis (Figure S14A). Several  
490 studies have focused on the importance of 17 $\beta$ -estradiol in protecting the retinal ganglion cell layer  
491 and preserving visual function in clinical<sup>29</sup> and basic<sup>25</sup> research by anti-inflammatory effect<sup>30</sup>. Our  
492 previous studies suggested that decreased sex hormone concentrations in glaucoma lead to a  
493 hyperinflammatory state, leading to faster rates of VF damage<sup>18,31</sup>. Thus, we hypothesized that  
494 aromatase defects might lead to a decrease in estradiol levels and an increase in androstenedione,

495 causing an inflammatory response and leading to retinal ganglion cell death in patient with glaucoma  
496 (Figure S14B). In addition, androstenedione converted to estrogens is catalyzed by the aromatase  
497 (Figure S14C). Furthermore, some of the metabolites might also be linked to PACG physiological  
498 processes that remain unclear, and future research in this field is needed. Sex hormones, including  
499 androstenedione, might be associated with glaucoma types such as POAG, normal-tension glaucoma,  
500 and pseudoexfoliation glaucoma<sup>32</sup>. The precise molecular mechanisms remain unclear. More  
501 research is essential to understand their relationship with different glaucoma types.

502 Furthermore, other studies have also found significant correlations between androstenedione and  
503 other diseases. For example, Javier et al.<sup>33</sup> found that androstenedione can predict the progression of  
504 Frailty Syndrome in patients with localized breast cancer treated with aromatase inhibitors.  
505 Adriaansen et al.<sup>34</sup> reported that diurnal salivary androstenedione levels in healthy volunteers for  
506 monitoring treatment efficacy of patients with congenital adrenal hyperplasia.

507 As far as our understanding goes, this is the initial investigation to methodically outline blood  
508 metabolites and scrutinize the diagnostic efficacy of a potential biomarker for PACG. Nevertheless,  
509 our study is not without its limitations: (1) The supplementary phase of our study was conducted  
510 with a restricted number of patients and healthy controls. Therefore, further investigations with larger  
511 sample sizes are necessary to confirm the diagnostic accuracy of serum androstenedione for the  
512 detection of primary angle-closure glaucoma (PACG). (2) Our study cohort exhibited uniform  
513 genetic and environmental traits, which may restrict the generalizability of our findings to  
514 populations with diverse ethnic or racial backgrounds. (3) Despite the matching of PACG patients  
515 and controls for age, gender, BMI, hypercholesterolemia, hypertension, diabetes, smoking, and  
516 drinking, it is possible that unidentified residual confounding factors could impact the observed  
517 metabolomic disparities. (4) Throughout the duration of the follow-up period, the majority of  
518 individuals received pharmacological treatment, and the study's follow-up period was limited to a  
519 mere two years. Consequently, the outcomes may have been impacted by either behavioral  
520 adjustments prompted by patients' cognizance of their medical condition or by any form of  
521 therapeutic intervention. (5) Despite our examination of the impact of hormone intake (including  
522 estrogen, progestagen, and anti-androgen), the potential influence of reproductive aging cannot be  
523 entirely dismissed. (6) Understanding the link between changes in androstenedione levels and

524 glaucoma severity might hinge on metabolic and anti-inflammatory pathways. However, the current  
525 study did not delve deeply into the mechanism verification. Further research is essential to  
526 comprehensively grasp the precise relationship between androstenedione and the severity of glaucoma,  
527 as well as the mechanisms at play.

## 528 **5. Conclusions**

529 In conclusion, androstenedione has been identified and validated through the use of widely-targeted  
530 LC-MS or targeted chemiluminescence immunoassay, demonstrating its ability to effectively  
531 differentiate between healthy individuals and those with PACG. Additionally, baseline  
532 androstenedione levels may serve as a valuable predictor of glaucomatous VF progression. However,  
533 further clinical and basic studies are required to confirm the clinical utility of serum androstenedione  
534 for early-stage PACG diagnosis, as well as its potential for monitoring/predicting VF progression and  
535 elucidating the underlying mechanisms linking androstenedione to PACG.

536

## 537 **Declarations**

538 **Ethics approval and consent to participate:** This study was approved by the Ethics Committee of  
539 Eye and ENT Hospital of Fudan University (EENT-2015011) and was conducted under the  
540 Declaration of Helsinki. All participants provided written informed consent prior to their  
541 participation.

542 **Consent for publication:** Not applicable.

543 **Availability of data and materials:** The datasets used and/or analyzed during the current study are  
544 available from the corresponding author on reasonable request.

545 **Competing interests:** No conflicting relationship exists for any author.

546 **Funding:** This work was supported by Youth Medical Talents – Clinical Laboratory Practitioner  
547 Program (2022-65), the National Natural Science Foundation of China (82302582), and Shanghai  
548 Municipal Health Commission Project (20224Y0317). The sponsor or funding organization had no  
549 role in the design or conduct of this research.

550 **Authors' contributions:** Shengjie Li, Shunxiang Gao and Wenjun Cao contributed to the study  
551 conception and design, data analysis, interpretation of the data, and drafting the manuscript. Yichao  
552 Qiu, Jun Ren, Zhendong Jiang, Yingzhu Li, Yunxiao Song, and Mingxi Shao contributed to the

553 interpretation of the data and critical revision of the manuscript. Shengjie Li, Yichao Qiu, Jun Ren,  
554 Yingzhu Li, Yunxiao Song, Xinghuai Sun, Shunxiang Gao and Mingxi Shao contributed to the  
555 collection of the data. All authors read and approved the final manuscript.

556 **Acknowledgements:** Not applicable.

557

558

559

560

561

## 562 **Reference**

- 563 1. Jonas, J. B. *et al.* Glaucoma. *Lancet* **390**, 2183–2193 (2017).
- 564 2. Liu, Y. *et al.* Glaucoma in rural China (the Rural Epidemiology for Glaucoma in China (REG-  
565 China)): a national cross-sectional study. *Br J Ophthalmol* [bjophthalmol-2021-320754](#) (2022)  
566 doi:10.1136/bjo-2021-320754.
- 567 3. Stein, J. D. *et al.* Differences in rates of glaucoma among Asian Americans and other racial  
568 groups, and among various Asian ethnic groups. *Ophthalmology* **118**, 1031–1037 (2011).
- 569 4. Tham, Y.-C. *et al.* Global prevalence of glaucoma and projections of glaucoma burden through  
570 2040: a systematic review and meta-analysis. *Ophthalmology* **121**, 2081–2090 (2014).
- 571 5. Song, W. *et al.* Prevalence of glaucoma in a rural northern china adult population: a population-  
572 based survey in kailu county, inner mongolia. *Ophthalmology* **118**, 1982–1988 (2011).
- 573 6. Stein, J. D., Khawaja, A. P. & Weizer, J. S. Glaucoma in Adults-Screening, Diagnosis, and  
574 Management: A Review. *JAMA* **325**, 164–174 (2021).
- 575 7. He, M. *et al.* Laser peripheral iridotomy for the prevention of angle closure: a single-centre,  
576 randomised controlled trial. *Lancet* **393**, 1609–1618 (2019).

- 577 8. Sun, X. *et al.* Primary angle closure glaucoma: What we know and what we don't know. *Prog*  
578 *Retin Eye Res* **57**, 26–45 (2017).
- 579 9. J, Y. *et al.* Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of  
580 response to corticosteroids. *EBioMedicine* **84**, (2022).
- 581 10. Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G. Metabolomics  
582 activity screening for identifying metabolites that modulate phenotype. *Nat Biotechnol* **36**, 316–  
583 320 (2018).
- 584 11. Hysi, P. G. *et al.* Ascorbic acid metabolites are involved in intraocular pressure control in the  
585 general population. *Redox Biol* **20**, 349–353 (2019).
- 586 12. Wang, Y., Hou, X.-W., Liang, G. & Pan, C.-W. Metabolomics in Glaucoma: A Systematic  
587 Review. *Invest Ophthalmol Vis Sci* **62**, 9 (2021).
- 588 13. Tang, Y. *et al.* Metabolomic Profiling of Aqueous Humor and Plasma in Primary Open Angle  
589 Glaucoma Patients Points Towards Novel Diagnostic and Therapeutic Strategy. *Front*  
590 *Pharmacol* **12**, 621146 (2021).
- 591 14. Rong, S. *et al.* Long-chain unsaturated fatty acids as possible important metabolites for primary  
592 angle-closure glaucoma based on targeted metabolomic analysis. *Biomed Chromatogr* **31**, (2017).
- 593 15. Kang, J. H. *et al.* Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma.  
594 *Invest Ophthalmol Vis Sci* **63**, 15 (2022).
- 595 16. Li, S. *et al.* Serum complement component 3, complement component 4 and complement  
596 component 1q levels predict progressive visual field loss in older women with primary angle  
597 closure glaucoma. *Br J Ophthalmol* [bjophthalmol-2021-320541](https://doi.org/10.1136/bjophthalmol-2021-320541) (2022)  
598 [doi:10.1136/bjophthalmol-2021-320541](https://doi.org/10.1136/bjophthalmol-2021-320541).

- 599 17. Li, S. *et al.* Association of systemic inflammation indices with visual field loss progression in  
600 patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches.  
601 *EPMA J* **12**, 659–675 (2021).
- 602 18. Li, S. *et al.* Association Between 17- $\beta$ -Estradiol and Interleukin-8 and Visual Field Progression  
603 in Postmenopausal Women with Primary Angle Closure Glaucoma. *Am J Ophthalmol* **217**, 55–  
604 67 (2020).
- 605 19. Chen, Y. *et al.* Lack of Association of rs1192415 in TGFBR3-CDC7 With Visual Field  
606 Progression: A Cohort Study in Chinese Open Angle Glaucoma Patients. *Front Genet* **9**, 488  
607 (2018).
- 608 20. Naghizadeh, F. & Holló, G. Detection of early glaucomatous progression with octopus cluster  
609 trend analysis. *J Glaucoma* **23**, 269–275 (2014).
- 610 21. Gong, L. *et al.* All-In-One Biomimetic Nanoplatfrom Based on Hollow Polydopamine  
611 Nanoparticles for Synergistically Enhanced Radiotherapy of Colon Cancer. *Small* **18**, e2107656  
612 (2022).
- 613 22. Obuchowski, N. A. & Zhou, X.-H. Prospective studies of diagnostic test accuracy when disease  
614 prevalence is low. *Biostatistics* **3**, 477–492 (2002).
- 615 23. Li, J. & Fine, J. On sample size for sensitivity and specificity in prospective diagnostic accuracy  
616 studies. *Stat Med* **23**, 2537–2550 (2004).
- 617 24. Qin, Y. *et al.* Association between plasma free fatty acid levels and primary angle-closure  
618 glaucoma based on a mass spectrometry metabolomics analysis. *Acta Ophthalmol* **100**, e204–  
619 e212 (2022).
- 620 25. Prokai-Tatrai, K. *et al.* 17 $\beta$ -estradiol eye drops protect the retinal ganglion cell layer and


- 621 preserve visual function in an in vivo model of glaucoma. *Mol Pharm* **10**, 3253–3261 (2013).
- 622 26. Madjedi, K. M. *et al.* The Association of Female Reproductive Factors with Glaucoma and  
623 Related Traits: A Systematic Review. *Ophthalmol Glaucoma* S2589-4196(22)00096–5 (2022)  
624 doi:10.1016/j.ogla.2022.06.003.
- 625 27. Feng, L. R., Barb, J. J., Allen, H., Regan, J. & Saligan, L. Steroid Hormone Biosynthesis  
626 Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate  
627 Cancer. *Front Cell Dev Biol* **9**, 642307 (2021).
- 628 28. Schiffer, L. *et al.* Human steroid biosynthesis, metabolism and excretion are differentially  
629 reflected by serum and urine steroid metabolomes: A comprehensive review. *J Steroid Biochem*  
630 *Mol Biol* **194**, 105439 (2019).
- 631 29. Vajaranant, T. S. *et al.* Racial Differences in the Effects of Hormone Therapy on Incident Open-  
632 Angle Glaucoma in a Randomized Trial. *Am J Ophthalmol* **195**, 110–120 (2018).
- 633 30. Engler-Chiurazzi, E. B., Brown, C. M., Povroznik, J. M. & Simpkins, J. W. Estrogens as  
634 neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. *Prog*  
635 *Neurobiol* **157**, 188–211 (2017).
- 636 31. Qiu, Y. *et al.* Association Between Sex Hormones and Visual Field Progression in Women With  
637 Primary Open Angle Glaucoma: A Cross-Sectional and Prospective Cohort Study. *Front Aging*  
638 *Neurosci* **13**, 756186 (2021).
- 639 32. Bailey, J. N. C. *et al.* Testosterone Pathway Genetic Polymorphisms in Relation to Primary  
640 Open-Angle Glaucoma: An Analysis in Two Large Datasets. *Invest Ophthalmol Vis Sci* **59**, 629–  
641 636 (2018).
- 642 33. García-Sánchez, J., Mafla-España, M. A., Torregrosa, M. D. & Cauli, O. Androstenedione and



643 Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One  
644 Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors.  
645 *Biomedicines* **10**, 1634 (2022).


646 34. Adriaansen, B. P. H. *et al.* Diurnal salivary androstenedione and 17-hydroxyprogesterone levels  
647 in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal  
648 hyperplasia. *Clin Endocrinol (Oxf)* **97**, 36–42 (2022).

649




650

651 **Figure 1.** Study design and workflow. A 5-phase study (discovery phase [discovery set 1, the  
652 discovery set 2], validation phase 1, validation phase 2, supplemental phase, and cohort phase)  
653 design. A: The workflow of the discovery phase, validation phase 1, supplemental phase, and cohort  
654 phase were analyzed by liquid chromatography-mass spectrometry (LC-MS) for untargeted  
655 metabolomics. B: The workflow of validation phase 2 was analyzed chemiluminescence  
656 immunoassay for targeted detection. C: A total of 440 patients and controls were recruited and  
657 assigned to discovery set 1 (n = 140), the discovery set 2 (n = 180), and validation set 1 (n = 120).  
658 The biomarker signature was identified on the metabolomic data from the discovery phase,  
659 comparing primary angle closure glaucoma (PACG) with control patients. These data were used as a  
660 discovery set for the algorithm. D: Validation phase 2 (n = 176) was included as the second  
661 validation cohort. E: Three measurements were performed in the supplemental phase. F: Cohort  
662 phase were performed to validate the predictive value of biomarker (n = 97).



664 **Figure 2.** Metabolic profiles discriminate participants with primary angle closure glaucoma (PACG)  
665 from normal controls (NC). A: Orthogonal projection to latent structure-discriminant analysis  
666 (OPLS-DA) score plot of the comparison between the PACG and NC groups in the discovery phase  
667 (discovery set 1 and discovery set 2). Samples in the encircled areas are within the 95% confidence  
668 interval. B: Volcano plot of differential metabolites. Metabolites with a fold change of  $<0.85$  and a  
669 false discovery rate (FDR) of  $<0.1$  were considered significantly down-regulated. Metabolites with a  
670 fold change of  $>1.15$  and an FDR of  $<0.1$  were considered significantly up-regulated. Changes in  
671 other metabolites were not significant (insignificant). C: Venn diagram displaying the 32 differential  
672 metabolites that were altered as biomarker candidates from the two comparisons in the discovery  
673 phase. D: Heatmap of differential metabolites in the discovery set 1 (Data were normalized to min-  
674 max). E: Heatmap of differential metabolites in the discovery set 2 (Data were normalized to min-  
675 max). FA: fatty acid.








676


677 **Figure 3.** Identification of a unique PACG-associated blood metabolite fingerprint and its behavior  
678 in the discovery phase. A: Heatmap of the area under the receiver-operating-characteristic curve

679 assessing the discriminating accuracy of each of the 32 metabolites in differentiating PACG from  
680 normal control in the discovery set 1 and discovery set 2. B: The eigenmetabolite of the 32-  
681 metabolite cluster between primary angle closure glaucoma (PACG) and control patients in the  
682 discovery set 1. C: The eigenmetabolite of the 32-metabolite cluster between primary angle closure  
683 glaucoma (PACG) and control patients in the discovery set 2. Wilcox test was used.





685 **Figure 4.** Biomarker discovery discriminates primary angle closure glaucoma (PACG) from normal  
 686 in the discovery phase. A: A heatmap of correlation analysis between ocular clinical characteristics  
 687 and 32 potential biomarkers in the discovery phase in PACG subjects. B: The serum level of  
 688 androstenedione between PACG( $42852 \pm 20767$ ) and normal( $33987 \pm 11113$ ) group in the discovery  
 689 set 1 (Unit for y-axis is peak areas). C: The serum level of androstenedione between PACG and  
 690 normal group in the discovery set 2 (Unit for y-axis is peak areas). D: Receiver operating  
 691 characteristic curves of androstenedione to discriminate PACG from normal in the discovery set 1. E:  
 692 Receiver operating characteristic curves of androstenedione to discriminate PACG from normal in  
 693 the discovery set 2. Independent student's t-test was used.




694

695 **Figure 5.** Biomarker validation in two independent validation phases to discriminate primary angle  
 696 closure glaucoma (PACG) from normal. A: The serum level of androstenedione between PACG and






697 normal group in validation phase 1 (Unit for y-axis is peak areas). B: The serum level of  
 698 androstenedione between PACG and normal group in validation phase 2 (Unit for y-axis is peak  
 699 areas). C: Receiver operating characteristic curves of androstenedione to discriminate PACG from  
 700 normal in validation phase 1. D: Receiver operating characteristic curves of androstenedione to  
 701 discriminate PACG from normal in validation phase 2. Independent student's t-test was used.



702

703 **Figure 6.** Specificity of circulating androstenedione in patients with primary angle closure glaucoma  
 704 (PACG) in supplemental phase. A: Sampling scheme and workflow to investigate the temporal  
 705 changes in androstenedione levels. B: Differential level of serum androstenedione between patients  
 706 with PACG before and three months after treatment (Unit for y-axis is peak areas). C: Sampling  
 707 scheme and workflow to determine whether aqueous humor levels of androstenedione were high in  
 708 patients with PACG. D: The aqueous humor level of androstenedione between PACG and cataract  
 709 (Unit for y-axis is peak areas). E: Heatmap of correlation analysis between ocular clinical

710 characteristics and aqueous humor level of androstenedione. F: Comparison means aqueous humor  
 711 levels of androstenedione between mild, moderate, and severe PACG (Unit for y-axis is peak areas).  
 712 G: 7 paired serum-aqueous humor samples from the same PACG patients were included (Unit for y  
 713 and x-axis is peak areas). A significant correlation between serum and aqueous humor levels of  
 714 androstenedione was observed. Kruskal-Wallis test and one-way ANOVA was used. \*P<0.05; \*\*: P<0.001.  
 715



716

717 **Figure 7.** Kaplan-Meier curves stratified by the men value in terms of androstenedione. A:  
718 male+female; B: Female; C: Male. We categorized study participants into 2 groups based on their  
719 mean levels of androstenedione.  
720

721 Table 1. The clinical and demographic characteristics of all subjects in the discovery and validation  
722 phases

	Normal (n=268)	PACG (n=348)	t/ $\chi^2$	p
<b>Discovery phase</b>				
<b>Discovery set 1</b>				
Number (n)	60	80		
Age (Years)	58.75±8.63	61.00±8.67	1.52	0.13
Sex ( Male , % )	24 ( 40.0 )	31 ( 38.8 )	0.02	0.88
BMI (Kg/m <sup>2</sup> )	24.04±5.27	23.36±2.44	0.99	0.33
Hypercholesterolemia (Yes , %)	6 (10)	9 (11.3)	0.06	0.81
Hypertension (Yes , %)	16 ( 26.7 )	18 ( 22.8 )	0.32	0.60
Diabetes (Yes , %)	1 ( 1.7 )	8 ( 10.1 )	3.96	0.10
Smoking (Yes , %)	5 ( 8.3 )	11 ( 13.9 )	0.99	0.42
Drinking (Yes , %)	7 ( 11.7 )	8 ( 10.1 )	0.1	0.76
Duration (Months)		10.45±12.43		
IOP (mmHg)	12.22±4.50	27.78±11.20	10.17	<0.001
VCDR	0.25±0.18	0.64±0.23	10.87	<0.001
AL (mm)		22.48±1.14		
ACD (mm)		1.86±0.55		
CCT (um)		534.04±41.26		
MS (dB)		12.46±8.75		
MD (dB)		14.67±8.94		
<b>Discovery set 2</b>				
Number (n)	80	100		
Age (Years)	62.54±6.74	63.14±9.04	0.49	0.62
Sex ( Male , % )	35 (43.8)	33 (33.0)	2.19	0.14
BMI (Kg/m <sup>2</sup> )	23.68±2.81	23.32±3.15	1.36	0.18
Hypercholesterolemia (Yes , %)	12 (15)	13 (13)	0.15	0.70
Hypertension (Yes , %)	26 (32.5)	33 (33.0)	0.01	0.94
Diabetes (Yes , %)	7 (8.8)	9 (9.0)	0.003	0.95
Smoking (Yes , %)	11 (13.8)	15 (15.0)	0.06	0.81
Drinking (Yes , %)	19 (23.8)	22 (22.0)	0.08	0.78
Duration (Months)		8.46±9.69		
IOP (mmHg)	11.45±5.21	25.80±12.55	8.329	<0.001
VCDR	0.27±0.14	0.61±0.22	10.48	<0.001
AL (mm)		22.43±0.75		
ACD (mm)		2.05±0.77		
CCT (um)		547.43±43.04		
MS (dB)		12.34±8.55		
MD (dB)		14.50±8.95		

### Validation phase 1

	Number (n)	50	70		
Age (Years)		57.47±8.17	60.34±10.11	1.66	0.10
Sex ( Male , % )		18 (36.0)	24 (34.3)	0.04	0.85
BMI (Kg/m <sup>2</sup> )		23.08±1.99	24.45±3.72	1.31	0.19
Hypercholesterolemia (Yes , %)		4 (8)	8 (11.4)	0.38	0.54
Hypertension (Yes , %)		17 (34.0)	21 (30.0)	0.22	0.64
Diabetes (Yes , %)		5 (10.0)	7 (10.0)	0.0	1.0
Smoking (Yes , %)		6 (12.0)	10 (14.3)	0.13	0.72
Drinking (Yes , %)		10 (20.0)	15 (21.4)	0.04	0.85
Duration (Months)			11.09±13.82		
IOP (mmHg)		12.90±4.11	28.46±9.80	11.55	<0.001
VCDR		0.24±0.17	0.60±0.21	10.87	<0.001
AL (mm)			22.44±0.83		
ACD (mm)			1.86±0.37		
CCT (um)			539.09±82.70		
MS (dB)			13.78±8.58		
MD (dB)			13.96±9.29		

### Validation phase 2

	Number (n)	78	98		
Age (Years)		56.55±11.53	60.26±15.41	1.77	0.08
Sex ( Male , % )		29 (37.2)	48 (49.0)	2.46	0.12
BMI (Kg/m <sup>2</sup> )		24.54±5.42	25.90±7.51	1.26	0.21
Hypercholesterolemia (Yes , %)		11 (14.1)	13 (13.3)	0.03	0.87
Hypertension (Yes , %)		19 (24.4)	31 (31.6)	0.26	0.61
Diabetes (Yes , %)		6 (7.7)	17 (17.3)	3.6	0.06
Smoking (Yes , %)		9 (11.5)	22 (22.4)	3.6	0.06
Drinking (Yes , %)		12 (15.4)	19 (19.4)	0.48	0.49
Duration (Months)			11.40±13.8		
IOP (mmHg)		13.40±5.43	29.20±11.20	10.07	<0.001
VCDR		0.30±0.19	0.68±0.23	10.41	<0.001
AL (mm)			23.20±1.72		
ACD (mm)			2.15±0.67		
CCT (um)			546.71±50.35		
MS (dB)			11.07±8.54		
MD (dB)			16.49±8.64		

723 BMI =body mass index; IOP = intraocular pressure, VCDR = vertical cup-to-disc ratio, AL = axial  
 724 length, CCT = central corneal thickness, ACD = anterior chamber depth, MD: visual field mean  
 725 deviation, MS: visual field mean sensitivity, PACG=primary angle closure glaucoma.

726

727 Table 2. Cox Proportional Hazards Regression Analysis to Assess the Value of Androstenedione  
728 Associated with Progression of PACG

	Univariate		Multivariate*	
	P	HR (95%CI)	P	HR (95%CI)
Age	<b>0.008</b>	<b>0.97 (0.95 to 0.99)</b>	0.22	0.98 (0.95 to 1.01)
Sex	0.87	0.95 (0.53 to 1.72)	0.73	1.15 (0.53 to 2.52)
IOP	0.59	1.007 (0.98 to 1.04)	0.75	0.99 (0.96 to 1.03)
VCDR	0.17	0.40 (0.11 to 1.46)	0.16	0.37 (0.092 to 1.46)
CCT	0.77	1.001 (0.10 to 1.007)	0.90	1.000 (0.99 to 1.007)
ACD	<b>0.03</b>	<b>1.63 (1.05 to 2.52)</b>	0.91	1.041 (0.51 to 2.13)
AL	<b>0.005</b>	<b>1.24 (1.07 to 1.44)</b>	0.35	1.12 (0.89 to 1.41)
MD	0.13	1.04 (0.99 to 1.08)	0.075	1.047 (0.10 to 1.10)
Androstenedione	<b>&lt;0.001</b>	<b>3.73 (1.84 to 7.57)</b>	<b>0.017</b>	<b>2.71 (1.20 to 6.10)</b>

729 IOP = intraocular pressure, VCDR = vertical cup-to-disc ratio, AL = axial length, CCT = central  
730 corneal thickness, ACD = anterior chamber depth, MD = mean deviation, PACG=primary angle  
731 closure glaucoma.

732 \*adjusted for BMI, diabetes (yes=1, no=0), hypertension (yes=1, no=0), hypercholesterolemia  
733 (yes=1, no=0), smoking (yes=1, no=0), and drinking (yes=1, no=0).

734